p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo

M. Cardinali, J. Jakus, S. Shah, J. F. Ensley, K. C. Robbins, W. A. Yeudall

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The excessive proliferation exhibited by cancer cells is frequently a result of their failure to adequately regulate cell cycle progression. In the present study, we developed a xenograft model of oral cancer in athymic mice, using squamous carcinoma cell lines and examined the ability of the cyclin- dependent kinase inhibitor p21 (WAF1/Cip1) to retard tumour growth in vivo, using a retroviral delivery system. Human p21 cDNA was cloned by polymerase chain reaction, expressed, and the encoded protein shown to have biological activity in in vitro kinase assays. Amphotropic retrovirus cultures which expressed recombinant p21 were generated and used to treat established squamous cell carcinoma xenografts. Two weeks following onset of treatment, tumours injected with p21 virus producer cells showed a reduction in size between 3- and 10-fold compared with tumours which received control cells which produced control virus alone. The data indicate that recombinant p21 may be of future use for therapeutic intervention in oral cancer.

Original languageEnglish
Pages (from-to)211-218
Number of pages8
JournalOral Oncology
Volume34
Issue number3
DOIs
Publication statusPublished - May 1998

Fingerprint

Squamous Cell Carcinoma
Mouth Neoplasms
Growth
Heterografts
Neoplasms
Cyclin-Dependent Kinase Inhibitor p21
Viruses
Therapeutic Uses
Retroviridae
Nude Mice
Cell Cycle
Phosphotransferases
Complementary DNA
Cell Line
Polymerase Chain Reaction
Proteins

Keywords

  • Cell cycle
  • Cip1
  • Gene therapy
  • Oral cancer
  • P21
  • sdil
  • Tumour suppressor
  • WAF1

ASJC Scopus subject areas

  • Oncology

Cite this

Cardinali, M., Jakus, J., Shah, S., Ensley, J. F., Robbins, K. C., & Yeudall, W. A. (1998). p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. Oral Oncology, 34(3), 211-218. https://doi.org/10.1016/S1368-8375(97)00083-3

p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. / Cardinali, M.; Jakus, J.; Shah, S.; Ensley, J. F.; Robbins, K. C.; Yeudall, W. A.

In: Oral Oncology, Vol. 34, No. 3, 05.1998, p. 211-218.

Research output: Contribution to journalArticle

Cardinali, M, Jakus, J, Shah, S, Ensley, JF, Robbins, KC & Yeudall, WA 1998, 'p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo', Oral Oncology, vol. 34, no. 3, pp. 211-218. https://doi.org/10.1016/S1368-8375(97)00083-3
Cardinali, M. ; Jakus, J. ; Shah, S. ; Ensley, J. F. ; Robbins, K. C. ; Yeudall, W. A. / p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. In: Oral Oncology. 1998 ; Vol. 34, No. 3. pp. 211-218.
@article{3a3d6744388f4afa9c4d3ec76dcc05e4,
title = "p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo",
abstract = "The excessive proliferation exhibited by cancer cells is frequently a result of their failure to adequately regulate cell cycle progression. In the present study, we developed a xenograft model of oral cancer in athymic mice, using squamous carcinoma cell lines and examined the ability of the cyclin- dependent kinase inhibitor p21 (WAF1/Cip1) to retard tumour growth in vivo, using a retroviral delivery system. Human p21 cDNA was cloned by polymerase chain reaction, expressed, and the encoded protein shown to have biological activity in in vitro kinase assays. Amphotropic retrovirus cultures which expressed recombinant p21 were generated and used to treat established squamous cell carcinoma xenografts. Two weeks following onset of treatment, tumours injected with p21 virus producer cells showed a reduction in size between 3- and 10-fold compared with tumours which received control cells which produced control virus alone. The data indicate that recombinant p21 may be of future use for therapeutic intervention in oral cancer.",
keywords = "Cell cycle, Cip1, Gene therapy, Oral cancer, P21, sdil, Tumour suppressor, WAF1",
author = "M. Cardinali and J. Jakus and S. Shah and Ensley, {J. F.} and Robbins, {K. C.} and Yeudall, {W. A.}",
year = "1998",
month = "5",
doi = "10.1016/S1368-8375(97)00083-3",
language = "English",
volume = "34",
pages = "211--218",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo

AU - Cardinali, M.

AU - Jakus, J.

AU - Shah, S.

AU - Ensley, J. F.

AU - Robbins, K. C.

AU - Yeudall, W. A.

PY - 1998/5

Y1 - 1998/5

N2 - The excessive proliferation exhibited by cancer cells is frequently a result of their failure to adequately regulate cell cycle progression. In the present study, we developed a xenograft model of oral cancer in athymic mice, using squamous carcinoma cell lines and examined the ability of the cyclin- dependent kinase inhibitor p21 (WAF1/Cip1) to retard tumour growth in vivo, using a retroviral delivery system. Human p21 cDNA was cloned by polymerase chain reaction, expressed, and the encoded protein shown to have biological activity in in vitro kinase assays. Amphotropic retrovirus cultures which expressed recombinant p21 were generated and used to treat established squamous cell carcinoma xenografts. Two weeks following onset of treatment, tumours injected with p21 virus producer cells showed a reduction in size between 3- and 10-fold compared with tumours which received control cells which produced control virus alone. The data indicate that recombinant p21 may be of future use for therapeutic intervention in oral cancer.

AB - The excessive proliferation exhibited by cancer cells is frequently a result of their failure to adequately regulate cell cycle progression. In the present study, we developed a xenograft model of oral cancer in athymic mice, using squamous carcinoma cell lines and examined the ability of the cyclin- dependent kinase inhibitor p21 (WAF1/Cip1) to retard tumour growth in vivo, using a retroviral delivery system. Human p21 cDNA was cloned by polymerase chain reaction, expressed, and the encoded protein shown to have biological activity in in vitro kinase assays. Amphotropic retrovirus cultures which expressed recombinant p21 were generated and used to treat established squamous cell carcinoma xenografts. Two weeks following onset of treatment, tumours injected with p21 virus producer cells showed a reduction in size between 3- and 10-fold compared with tumours which received control cells which produced control virus alone. The data indicate that recombinant p21 may be of future use for therapeutic intervention in oral cancer.

KW - Cell cycle

KW - Cip1

KW - Gene therapy

KW - Oral cancer

KW - P21

KW - sdil

KW - Tumour suppressor

KW - WAF1

UR - http://www.scopus.com/inward/record.url?scp=0032078707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032078707&partnerID=8YFLogxK

U2 - 10.1016/S1368-8375(97)00083-3

DO - 10.1016/S1368-8375(97)00083-3

M3 - Article

C2 - 9692056

AN - SCOPUS:0032078707

VL - 34

SP - 211

EP - 218

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 3

ER -